X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Mirvetuximab was readily combined and well tolerated with standard dosing of carboplatin and bevacizumab, with a manageable adverse event (AE) profile as anticipated for this triplet based on the side effect profiles of each agent.
Lead Product(s): Mirvetuximab Soravtansine,Carboplatin,Bevacizumab
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
BePharma 2024
Not Confirmed
Contact SupplierDetails:
SB27 is the proposed biosimilar to keytruda (pembrolizumab), being investigated for the treatment of metastatic non-squamous non-small cell lung cancer.
Lead Product(s): Pembrolizumab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: SB27
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
AK104 (cadonilimab) is a PD-1/CTLA-4 bi-specific antibody which is being investigated in phase 3 in combination with chemotherapy (Carboplatin, Pemetrexed, Paclitaxel) for PD-L1 negative non-small cell lung cancer.
Lead Product(s): Cadonilimab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: AK104
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with chemotherapy for the treatment of previously untreated EGFR exon 20 insertion mutation-positive NSCLC.
Lead Product(s): Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
GEN-1 (IMNN-001) is a DNA-based interleukin-12 (IL-12) immunotherapy, which is being evaluated in combination with bevacizumab for the treatement of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: GEN-1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is being evaluated for the treatment of first-line gastric or gastroesophageal junction cancers.
Lead Product(s): Tislelizumab,Carboplatin,Fluoropyrimidine
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Tevimbra (tislelizumab) is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is being evaluated for the treatment of advanced squamous NSCLC.
Lead Product(s): Tislelizumab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Tevimbra
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Keytruda (pembrolizumab) is a humanized monoclonal anti-PD-1 therapy that works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is being evaluated for the treatment of primary advanced or recurrent endometrial carcinoma.
Lead Product(s): Pembrolizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Keytruda
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
G1T28 (trilaciclib) is an IV-administered transient CDK 4/6 inhibitor, which is being evaluated in combination with gemcitabine & carboplatin for the treatment of metastatic triple negative breast cancer.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. It is being developed for the treatment of triple negative breast cancer, non-small cell lung cancer & pancreatic cancer.
Lead Product(s): Nadunolimab,Carboplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: CAN04
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with chemotherapy for the treatment of resectable stage IIA to IIIB non-small cell lung cancer.
Lead Product(s): Nivolumab,Carboplatin,Cisplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
The collaboration aims to focus on advancing and potentially accelerating the development of domvanalimab for the treatment of Metastatic Non-Small Cell Lung Cancer.
Lead Product(s): Zimberelimab,Domvanalimab,Carboplatin
Therapeutic Area: Oncology Product Name: GS-0122
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Arcus Biosciences
Deal Size: $1,225.0 million Upfront Cash: $375.0 million
Deal Type: Collaboration January 29, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is under phase 3 clinical development for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC).
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
Rybrevant (amivantamab) is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity. It is being evaluated in combination with lazertinib for the treatment of patients with EGFR-mutated non-small cell lung cancer.
Lead Product(s): Amivantamab,Lazertinib,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
The collaboration aims to help evaluate therapeutic response and provide molecular insights for Rutgers Cancer Institute trial examining early-stage triple-negative breast cancer patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.
Lead Product(s): Doxorubicin Hydrochloride,Carboplatin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rutgers Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1)-blocking antibody, plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Merck's MK-7684A vibostolimab/pembrolizumab, an investigational coformulation of vibostolimab, an anti-TIGIT antibody, and Keytruda, anti-PD-1 therapy, with or without Carboplatin for the treatment of patients with metastatic non-small cell lung cancer.
Lead Product(s): Vibostolimab,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: MK-7684A
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with chemotherapy for the treatment of adult patients with advanced egfr-mutated non-small cell lung cancer after failure of prior therapy.
Lead Product(s): Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Details:
Company submits sNDA seeking approval of rybrevant (amivantamab-vmjw), a EGFR and MET inhibitor candidate, plus chemotherapy for the treatment of patients with EGFR-mutated non-small cell lung cancer Who progressed on or after osimertinib.
Lead Product(s): Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1 inhibitor which is being developed for the treatment of patients with primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is being evaluated for the treatment of primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated in combination with chemotherapy for the treatment of previously untreated EGFR exon 20 insertion mutation-positive NSCLC.
Lead Product(s): Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that is investigated in combination with bevacizumab for the treatment of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
Opdivo (nivolumab), a PD-1 blocking antibody, which is investigated in combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma.
Lead Product(s): Nivolumab,Ipilimumab,Carboplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Tagrisso (osimertinib) is kinase inhibitor of the epidermal growth factor receptor (EGFR), which is investigated in combination with chemotherapy for patients with EGFR-mutated advanced lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
Under the terms of the arrangement, ST will be responsible for all commercial, medical, regulatory and distribution activities for oregovomab in its key territories of Australia, New Zealand, Singapore, Thailand, Vietnam, Brunei and Malaysia.
Lead Product(s): Oregovomab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: MAb-B43.13
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CanariaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2023
Details:
Under the agreement, Hikma gains right for MAb-B43.13 (oregovomab), a murine monoclonal antibody, being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer, in the Middle East and North Africa (MENA) region.
Lead Product(s): Oregovomab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: MAb-B43.13
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CanariaBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 10, 2023
Details:
Rybrevant (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET, which is investigated in combination with amivantamab for the first-line treatment of adult patients with advanced non-small cell lung cancer.
Lead Product(s): Amivantamab-vmjw,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2023
Details:
Henlius will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for Phase III trial evaluating the efficacy and safety of serplulimab, a novel anti-PD-1 antibody, in patients with Extensive-Stage Small Cell Lung Cancer.
Lead Product(s): Serplulimab,Carboplatin,Etoposide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hengenix Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 03, 2023
Details:
The proceeds will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their IND application to evaluate DK210 (EGFR).
Lead Product(s): DK210,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: MPM BioImpact
Deal Size: $41.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 28, 2023
Details:
IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that is investigated for the treatment of epithelial ovarian cancer.
Lead Product(s): IMNN-001,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: IMNN-001
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
CPI-0209 (tulmimetostat) is an investigational compound designed to exert anti-tumor activity by inhibiting the EZH2 and EZH1, which is investigated for the treatment of endometrial cancer.
Lead Product(s): Tulmimetostat,Carboplatin
Therapeutic Area: Oncology Product Name: CPI-0209
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
RYBREVANT (amivantamab-vmjw), a fully-human bispecific antibody targeting EGFR and MET, which is investigated for the treatment of EGFR exon 19 deletions (ex19del) or L858R substitution NSCLC.
Lead Product(s): Amivantamab-vmjw,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Rybrevant (amivantamab-vmjw) is being developed in combination with chemotherapy (carboplatin-pemetrexed) in patients with newly diagnosed advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Lead Product(s): Amivantamab-vmjw,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: Rybrevant
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2023
Details:
JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancer.
Lead Product(s): Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tanner Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC).
Lead Product(s): IPH5201,Durvalumab,Carboplatin
Therapeutic Area: Oncology Product Name: IPH5201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
Genelux will use the net proceeds for advancement of clinical programs, including the Phase 3 registrational trial of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, non-pathogenic oncolytic vaccinia virus, in patients with platinum-resistant/refractory ovarian cancer.
Lead Product(s): Olvimulogene Nanivacirepvec,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Product Name: Olvi-Vec
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Benchmark Company
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 12, 2023
Details:
Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is been validated by EU for dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Lead Product(s): Dostarlimab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: Jemperli
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2023
Details:
The Phase 3 CheckMate -9LA trial demonstrating durable, long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy compared to four cycles of chemotherapy alone in previously untreated patients with NSCLC.
Lead Product(s): Nivolumab,Ipilimumab,Carboplatin
Therapeutic Area: Oncology Product Name: Opdivo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2023
Details:
Cosela (Trilaciclib hydrochloride), an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes.
Lead Product(s): Trilaciclib,Gemcitabine,Carboplatin
Therapeutic Area: Oncology Product Name: Cosela
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2023
Details:
Debio 0123 is a brain-penetrant, highly selective WEE1 kinase inhibitor combines with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC).
Lead Product(s): Debio 0123,Etoposide,Carboplatin
Therapeutic Area: Oncology Product Name: Debio 0123
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
IMP321 (Eftilagimod Alpha) is an antigen presenting cell activator for the treatment of cancer, capitalising on LAG-3’s to stimulate both innate and adaptive immunity. It is being investigated in phase II trial in soft tissue sarcoma in neoadjuvant setting.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
IMP321 (eftilagimod alpha) binds and activates LAG-3 leading in expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It is being investigated for NSCLC in combination with pembrolizumab.
Lead Product(s): Eftilagimod Alpha,Pembrolizumab,Carboplatin
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases. It is being investigated in patient with Stage IIIB-IIIC or Stage IV epidermal growth factor receptor-mutated NSCLC.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
